WALTHAM, Mass. & SINGAPORE, April 26 (Bernama-BUSINESS WIRE) --
PerkinElmer, Inc., a global leader focused on improving the health and
safety of people and the environment, and the Genome Institute of
Singapore (GIS), a biomedical sciences research institute under
Singapore’s Agency for Science, Technology and Research (A*STAR), today
announced the opening of the PerkinElmer-GIS Centre for Precision
Oncology. Leaders from PerkinElmer and GIS attended the official opening
ceremony today and discussed objectives for the joint research
laboratory.
The joint laboratory aims to develop a state-of-the-art high-throughput screening (HTS) platform to predict therapeutic sensitivity in next-generation patient-derived tumor models in real-time, with the ultimate goal of bringing precision oncology research results into the clinic. Specifically, the platform will utilize sequence-informed studies and HTS/HCS focused compound library screens to test the efficacy of different standard of care and pathway-specific inhibitors in 3D tumor micro-spheroid culture models derived either directly from patient primary tumors or patient-derived models (PDX).
http://mrem.bernama.com/viewsm.php?idm=26690
The joint laboratory aims to develop a state-of-the-art high-throughput screening (HTS) platform to predict therapeutic sensitivity in next-generation patient-derived tumor models in real-time, with the ultimate goal of bringing precision oncology research results into the clinic. Specifically, the platform will utilize sequence-informed studies and HTS/HCS focused compound library screens to test the efficacy of different standard of care and pathway-specific inhibitors in 3D tumor micro-spheroid culture models derived either directly from patient primary tumors or patient-derived models (PDX).
No comments:
Post a Comment